Nasal spray user
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

LTR Pharma (ASX:LTP) has announced its nasal spray ‘viagra drug’ SPONTAN has been prescribed by a Brisbane-based men’s health expert under the drug regulator’s Special Access Scheme (SAS).

The company listed in the dying days of 2023, and it’s had an interesting debut year on the ASX. In June it saw its shares jump 58%; 1Y gains currently sit above +300%.

In a way, LTR Pharma is kind of like the Droneshield of the Healthcare sector right now (ignoring that latter stocks’ recent price action.) The stock has garnered interest from the retail end of the investing ecosystem, but also from fund managers on the east coast.

Today’s news from LTR Pharma inks the second prescription under the TGA scheme this week – on Monday, the company saw a prescription from the Australia-based Restorative Sexual Health Clinic.

The company’s ultimate value proposition is that its drug SPONTAN is fast-acting, unlike its foremost competitor product viagra, which takes longer to kick in.

That rapid onset makes all the difference in contexts its intended for, and has led fund managers to calculate serious valuations.

“SPONTAN meets the needs of my patients where regular PDE5 inhibitor tablets do not,” Dr. Tom Silva said on Thursday – the men’s health expert in question part of today’s announcement from LTP.

“This represents another significant step in our strategy to introduce SPONTAN to the market through a carefully managed approach working with knowledgeable medical practitioners,” LTR Pharma Chairman Lee Rodne added.

LTP last traded at 85cps.

LTP by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…